Level Four Advisory Services’s Neurocrine Biosciences NBIX Stock Holding History

Level Four Advisory Services’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-5,070	Closed	-$668K	–	838
2024 Q1	$668K	Buy	5,070 +128	+3%	+$17.5K	0.04%	383
2023 Q4	$651K	Buy	+4,942	New	+$569K	0.04%	388
2023 Q1	–	Sell	-5,772	Closed	-$689K	–	802
2022 Q4	$689K	Sell	5,772 -1,933	-25%	-$226K	0.05%	327
2022 Q3	$818K	Sell	7,705 -4,761	-38%	-$483K	0.08%	233
2022 Q2	$1.22M	Buy	12,466 +7,452	+149%	+$688K	0.11%	188
2022 Q1	$470K	Buy	+5,014	New	+$425K	0.04%	410

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Level Four Advisory Services's NBIX Position: Q2 2024 in Review

Level Four Advisory Services sold out of Neurocrine Biosciences (NBIX) in Q2 2024, closing a stake of 5,070 shares — an estimated $668K sold.

Level Four Advisory Services first reported a position in NBIX in Q1 2022 and held it in 6 quarters. The position peaked at $1.22M in Q2 2022. 594 funds tracked by Wall St. Rank hold NBIX as of Q2 2024.

Level Four Advisory Services reported no remaining Neurocrine Biosciences position as of Q2 2024 after selling out during the quarter.
Level Four Advisory Services sold 5,070 Neurocrine Biosciences shares in Q2 2024, an estimated $668K.
Level Four Advisory Services first reported a position in Neurocrine Biosciences in Q1 2022 and held it in 6 quarters.
Level Four Advisory Services's Neurocrine Biosciences position peaked at $1.22M in Q2 2022.
594 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2024.

Based on Level Four Advisory Services's 13F filing for Q2 2024, filed 9 Aug 2024.